IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob L who wrote (1562)	5/20/1998 3:57:00 PM
From: Maurice Winn	1 Recommendation Read Replies (1) of 1762

No, CHOP alone is much less. I saw a bunch of numbers at haematology a couple of days ago and it was in the 60s or 70s. With the biggest number [various stages etc] in the low 80s I think. Maybe an oncologist here could quote the statistical facts. There seems no harm from using Rituxan - other than some opportunistic infections such as tuberculosis might be a risk [it must be a risk since you have B-cells to help you stay alive]. So if you get a bonus stay alive boost of 10% or maybe even 20% then that is a very good investment. Deaths from infections must be less than 1%. They do that much damage with leukaemia, thyroid cancer etc from radiation and then there is all the CHOP damage too. Any dead NHL cell is a good one! And the sooner the better, before they breed. Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next